相似文献
1
The Outcome and Safety of Re-challenge Lutetium-177 PSMA (Lu-PSMA) Therapy with Low-Dose Docetaxel as a Radiosensitizer-a Promising Combination in Metastatic Castrate-Resistant Prostate Cancer (mCRPC): a Case Report.
Nucl Med Mol Imaging. 2021 Jun;55(3):136-140. doi: 10.1007/s13139-021-00696-5. Epub 2021 Apr 13.
2
Safety and Efficacy of [Lu]-PSMA-I&T Radioligand Therapy in Octogenarians with Metastatic Castration-Resistant Prostate Cancer: Report on 80 Patients over the Age of 80 Years.
J Nucl Med. 2023 Aug;64(8):1244-1251. doi: 10.2967/jnumed.122.265259. Epub 2023 Jun 15.
3
A Single-Arm, Low-Dose, Prospective Study of Lu-EB-PSMA Radioligand Therapy in Patients with Metastatic Castration-Resistant Prostate Cancer.
J Nucl Med. 2023 Apr;64(4):611-617. doi: 10.2967/jnumed.122.264857. Epub 2022 Nov 3.
4
177 Lu-PSMA-617 radioligand therapy of metastatic castration-resistant prostate cancer: Initial 254-patient results from a prospective registry (REALITY Study).
Eur J Nucl Med Mol Imaging. 2022 Feb;49(3):1075-1085. doi: 10.1007/s00259-021-05525-7. Epub 2021 Sep 7.
5
Renal outcomes of radioligand therapy: experience of lutetium-prostate-specific membrane antigen ligand therapy in metastatic castrate-resistant prostate cancer.
Clin Kidney J. 2019 Aug 14;13(6):1049-1055. doi: 10.1093/ckj/sfz101. eCollection 2020 Dec.
6
Lu-PSMA-617 versus docetaxel in chemotherapy-naïve metastatic castration-resistant prostate cancer: a randomized, controlled, phase 2 non-inferiority trial.
Eur J Nucl Med Mol Imaging. 2022 Apr;49(5):1754-1764. doi: 10.1007/s00259-021-05618-3. Epub 2021 Nov 29.
7
Examining Absorbed Doses of Indigenously Developed Lu-PSMA-617 in Metastatic Castration-Resistant Prostate Cancer Patients at Baseline and During Course of Peptide Receptor Radioligand Therapy.
Cancer Biother Radiopharm. 2021 Apr;36(3):292-304. doi: 10.1089/cbr.2020.3640. Epub 2020 May 5.
8
Prostate-Specific Membrane Antigen Radioligand Therapy Using Lu-PSMA I&T and Lu-PSMA-617 in Patients with Metastatic Castration-Resistant Prostate Cancer: Comparison of Safety, Biodistribution, and Dosimetry.
J Nucl Med. 2022 Aug;63(8):1199-1207. doi: 10.2967/jnumed.121.262713. Epub 2021 Dec 9.
9
Combined Lu-PSMA-617 PRLT and abiraterone acetate versus Lu-PSMA-617 PRLT monotherapy in metastatic castration-resistant prostate cancer: An observational study comparing the response and durability.
Prostate. 2021 Nov;81(15):1225-1234. doi: 10.1002/pros.24219. Epub 2021 Sep 1.
10
Intermittent Radioligand Therapy with Lu-PSMA-617 for Oligometastatic Castration-Resistant Prostate Cancer.
Cancers (Basel). 2023 Sep 17;15(18):4605. doi: 10.3390/cancers15184605.
引用本文的文献
1
Framework to calculate Ac, Lu, and Tb radiation dose and biological effect in metastatic castration-resistant prostate cancer treatment.
Med Phys. 2025 Aug;52(8):e18035. doi: 10.1002/mp.18035.
2
Radionuclides Landscape in Prostate Cancer Theranostics.
Int J Mol Sci. 2025 Jul 14;26(14):6751. doi: 10.3390/ijms26146751.
3
Bone metastases of prostate cancer: Molecular mechanisms, targeted diagnosis and targeted therapy (Review).
Oncol Rep. 2025 Apr;53(4). doi: 10.3892/or.2025.8879. Epub 2025 Feb 21.
4
Is Extraordinary Response and Long-Term Remission of Metastatic Castration-Resistant Prostate Cancer (mCRPC) After [¹⁷⁷Lu]Lu-PSMA Radioligand Therapy Due to an Immunomodulatory Effect (Radiovaccination)? A Dual Center Experience on Super-Responders.
Cancers (Basel). 2025 Jan 31;17(3):476. doi: 10.3390/cancers17030476.
5
Future Treatment Strategies for Cancer Patients Combining Targeted Alpha Therapy with Pillars of Cancer Treatment: External Beam Radiation Therapy, Checkpoint Inhibition Immunotherapy, Cytostatic Chemotherapy, and Brachytherapy.
Pharmaceuticals (Basel). 2024 Aug 5;17(8):1031. doi: 10.3390/ph17081031.
6
PSMA radioligand therapy rechallenging: expanding the therapeutic possibilities in metastatic castration resistant prostate cancer.
Eur J Nucl Med Mol Imaging. 2024 Nov;51(13):4163-4164. doi: 10.1007/s00259-024-06870-z.
7
Efficacy and safety of rechallenge [Lu]Lu-PSMA-617 RLT after initial partial remission in patients with mCRPC: evaluation of a prospective registry (REALITY study).
Eur J Nucl Med Mol Imaging. 2024 Nov;51(13):4151-4162. doi: 10.1007/s00259-024-06825-4. Epub 2024 Jul 15.
8
PSMA-targeted radiotheranostics in modern nuclear medicine: then, now, and what of the future?
Theranostics. 2024 May 13;14(8):3043-3079. doi: 10.7150/thno.92612. eCollection 2024.
9
Towards Improving the Efficacy of PSMA-Targeting Radionuclide Therapy for Late-Stage Prostate Cancer-Combination Strategies.
Curr Oncol Rep. 2023 Nov;25(11):1363-1374. doi: 10.1007/s11912-023-01458-6. Epub 2023 Oct 20.
10
Lu-PSMA Radioligand Therapy Is Favorable as Third-Line Treatment of Patients with Metastatic Castration-Resistant Prostate Cancer. A Systematic Review and Network Meta-Analysis of Randomized Controlled Trials.
Biomedicines. 2021 Aug 19;9(8):1042. doi: 10.3390/biomedicines9081042.
本文引用的文献
1
Phase I trial of docetaxel plus lutetium-177-labeled anti-prostate-specific membrane antigen monoclonal antibody J591 (Lu-J591) for metastatic castration-resistant prostate cancer.
Urol Oncol. 2020 Nov;38(11):848.e9-848.e16. doi: 10.1016/j.urolonc.2020.05.028. Epub 2020 Jun 27.
2
PSMA-Based Theranostics: A Step-by-Step Practical Approach to Diagnosis and Therapy for mCRPC Patients.
Semin Nucl Med. 2020 Jan;50(1):98-109. doi: 10.1053/j.semnuclmed.2019.07.003. Epub 2019 Aug 21.
3
EANM procedure guidelines for radionuclide therapy with Lu-labelled PSMA-ligands (Lu-PSMA-RLT).
Eur J Nucl Med Mol Imaging. 2019 Nov;46(12):2536-2544. doi: 10.1007/s00259-019-04485-3. Epub 2019 Aug 22.
4
Exceptional 4-year response to Lu-PSMA radioligand therapy in metastatic castration-resistant prostate cancer.
Eur J Nucl Med Mol Imaging. 2019 Sep;46(10):2212-2213. doi: 10.1007/s00259-019-04410-8. Epub 2019 Jul 4.
5
Peptide Receptor Radionuclide Therapy Combined With Chemotherapy in Patients With Neuroendocrine Tumors.
Clin Nucl Med. 2019 May;44(5):e329-e335. doi: 10.1097/RLU.0000000000002532.
6
Outcome and safety of rechallenge [Lu]Lu-PSMA-617 in patients with metastatic prostate cancer.
Eur J Nucl Med Mol Imaging. 2019 May;46(5):1073-1080. doi: 10.1007/s00259-018-4222-x. Epub 2018 Nov 24.
7
Early Experience of Rechallenge Lu-PSMA Radioligand Therapy After an Initial Good Response in Patients with Advanced Prostate Cancer.
J Nucl Med. 2019 May;60(5):644-648. doi: 10.2967/jnumed.118.215715. Epub 2018 Nov 15.
8
Dosimetric analysis of patients with gastro entero pancreatic neuroendocrine tumors (NETs) treated with PRCRT (peptide receptor chemo radionuclide therapy) using Lu-177 DOTATATE and capecitabine/temozolomide (CAP/TEM).
Br J Radiol. 2018 Nov;91(1091):20170172. doi: 10.1259/bjr.20170172. Epub 2018 Jul 27.
9
Synthesis and Biologic Evaluation of a Novel F-Labeled Adnectin as a PET Radioligand for Imaging PD-L1 Expression.
J Nucl Med. 2018 Mar;59(3):529-535. doi: 10.2967/jnumed.117.199596. Epub 2017 Oct 12.
10
Concentration-dependent radiosensitizing effect of docetaxel in esophageal squamous cell carcinoma cells.
Int J Oncol. 2016 Feb;48(2):517-24. doi: 10.3892/ijo.2015.3291. Epub 2015 Dec 14.
Zotero 插件